Resources Repository
-
ReviewPublication 2001Modeling for Health Care and Other Policy Decisions: Uses, Roles and Validity
This is a review article of the role of modeling approaches to guide decision making …
This is a review article of the role of modeling approaches to guide decision making in health care and other domains. The role of models to support recommendations on the cost-effective use of medical technologies and pharmaceuticals is controversial. At the heart of the controversy is the degree to which experimental or other empirical evidence should be required prior to model use. The authors argue that the controversy stems in part from a misconception that…
Evidence Synthesis | Mathematical Models | Priority Setting/Ethics | Technology Assessment | Environmental Health | Health Systems | Policy/Regulation | Business/Industry | Climate/Environment | Economics/Finance | Energy/Engineering | Government/Law | Health/Medicine | North America -
BookPublication 1996Cost-Effectiveness in Health and Medicine, 1st Edition
In 1993, the US Public Health Service convened a panel of 13 nongovernment scientists and …
In 1993, the US Public Health Service convened a panel of 13 nongovernment scientists and scholars with expertise in economics, clinical medicine, ethics, and statistics to review the state of cost-effectiveness analysis and to develop recommendations for its conduct and use in health and medicine. Publishing their results in 1996, they proposed the most explicit set of guidelines (together with their rationale) ever defined on the conduct of CEAs. The panel recommended analysts include a "reference-case"…
Evidence Synthesis | Value of Information | Preferences/Values | Priority Setting/Ethics | Costing Methods | Health Outcomes | Cost-Effectiveness Analysis | Health Systems | Policy/Regulation | Economics/Finance | Health/Medicine | North America -
ReviewPublication 2023Modelling the Cost Effectiveness of Treatments for Parkinson's Disease: Methodological Review
This article systematically reviewed the methodological quality of economic evaluation models for treating motor symptoms …
This article systematically reviewed the methodological quality of economic evaluation models for treating motor symptoms in Parkinson’s disease in studies published post-2010. Methods included a systematic literature search using databases such as PubMed, EconLit, Cochrane, and several UK National Health Service databases, covering March 2010 to July 2022. The quality of the identified studies was assessed using a checklist from the German Scientific Working Group. Results showed that 20 studies were evaluated, most employing Markov…
Evidence Synthesis | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health/Medicine -
ReviewPublication 2023Health Economic Research Assessing the Value of Early Detection of Cardiovascular Disease: Systematic Review
This systematic review assesses the cost-effectiveness of recent early detection strategies for cardiovascular disease (CVD) …
This systematic review assesses the cost-effectiveness of recent early detection strategies for cardiovascular disease (CVD) in at-risk adult populations. Methods included searching PubMed and Scopus for articles published between January 2016 and May 2022. The first reviewer screened all articles, while a second reviewer independently validated a random 10% sample. Discrepancies were resolved through discussion, with a third reviewer involved if necessary. Costs were standardized to 2021 euros. Reporting quality was evaluated using the CHEERS…
Evidence Synthesis | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health/Medicine -
ReviewPublication 2023Economic & Humanistic Burden of Osteoarthritis: Systematic Review of Large Sample Studies
This study systematically reviewed and updated the economic and humanistic burden of osteoarthritis (OA) reported …
This study systematically reviewed and updated the economic and humanistic burden of osteoarthritis (OA) reported by large sample studies since 2016. Medline (via Ovid) and Embase were searched using an updated strategy based on a previous review. Studies with a sample size ≥1000 that measured direct or indirect costs or health-related quality of life (HRQL) of OA were included. Pairs of reviewers independently screened studies, and an arbitrator resolved discrepancies. The Kappa value for agreement…
Evidence Synthesis | Preferences/Values | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health/Medicine | Global -
ReviewPublication 2023Inclusion of Environmental Spillovers in Applied Economic Evaluations of Healthcare Products
This review examines the inclusion of environmental spillovers in economic evaluations of healthcare products and …
This review examines the inclusion of environmental spillovers in economic evaluations of healthcare products and health technology assessments (HTA). Environmental spillovers, such as CO2 emissions, water and energy consumption, and waste disposal, significantly impact human and planetary health but are often excluded from HTAs. The review's objective is to identify economic evaluations and guidelines incorporating environmental dimensions. Methods included electronic searches of PubMed, Scopus, and EMBASE, as well as official health agencies' guidelines. Documents were…
Evidence Synthesis | Cost-Effectiveness Analysis | Technology Assessment | Environmental Health | Climate/Environment | Health/Medicine | Global -
ReviewPublication 2023Systematic Literature Review of Gaps and Challenges in Value Assessment of Biosimilars: ISPOR Special Interest Group Report
This study addresses the gaps and challenges in the value assessment of biosimilars and proposes …
This study addresses the gaps and challenges in the value assessment of biosimilars and proposes potential approaches to mitigate them. A multidisciplinary team of biosimilar experts conducted a systematic review of literature and engaged in review rounds to identify these challenges. The article suggests that health technology assessment agencies should accept the comparability exercise approved by regulatory authorities and conduct price comparisons for biosimilars reimbursed for the same indication as the reference biologic. In cases…
Evidence Synthesis | Preferences/Values | Technology Assessment | Policy/Regulation | Health/Medicine -
ReviewPublication 2021Review of Web-Based Tools for Value-of-Information Analysis
Value-of-information analysis (VOI) is an analytic approach used to inform research priorities, guide clinical trial …
Value-of-information analysis (VOI) is an analytic approach used to inform research priorities, guide clinical trial design, and provide information for decisions about reimbursement. The authors review existing web-based tools to facilitate VOI calculations. These include Sheffield Accelerated Value of Information (SAVI), the web interface to the BCEA (Bayesian Cost-Effectiveness Analysis) R package (BCEAweb), Rapid Assessment of Need for Evidence (RANE), and Value of Information for Cardiovascular Trials and Other Comparative Research (VICTOR).
Value of Information | Decision Theory | Priority Setting/Ethics | Cost-Effectiveness Analysis | Economics/Finance | Health/Medicine -
ReviewPublication 2022Systematic Review of Economic Evaluations of COVID-19 Interventions: Non-Health Impacts and Distributional Issues
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether …
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether they incorporated non-health impacts and distributional concerns. Among the 70 articles included, more than half (56%) included at least one non-health impact, although only 21% incorporated non-economic consequences. Only 17% examined subgroups of interest. The median ICER for the entire sample was $67,000/quality-adjusted life-year (QALY) (interquartile range [IQR] $9000-$893,000/QALY). Interventions including a pharmaceutical component yielded a median ICER of $93,000/QALY (IQR…
Evidence Synthesis | Cost-Effectiveness Analysis | Infectious Diseases | Social Determinants | Culture/Society | Economics/Finance | Health/Medicine | North America